Lawrence Garbo, MD
Hematology & Oncology · Albany, NYNPI 1740276484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Medical Device Business Services, Inc. at 27.8% of the total. Reporting peaked in 2019 at $260 and has fallen 75.9% since, to $63 in 2021. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 7 payments — averaging $48.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$94
- Novartis$84
- Genentech USA, Inc.$81
- Gilead$38
- Incyte Corporation$25
- E.r. Squibb & Sons, L.L.C.$15
Across 452 payments — averaging $2568.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$175K
- Biontech SE$154K
- E.r. Squibb & Sons, L.L.C.$142K
- Merck$123K
- Eisai Inc.$122K
- Takeda Pharmaceuticals U.S.A., Inc.$121K
- plus $325K from 9 others
What the payments were for
- Food & beverage$31092%
- Education$278%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 1 | $94 |
| Novartis | 1 | $84 |
| Genentech USA, Inc. | 1 | $81 |
| Gilead | 2 | $38 |
| Incyte Corporation | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$337 in reported general payments places this provider in the 25th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $387,870 |
| SprycelDasatinib | 12 | $243,090 |
| Lenalidomide | 18 | $228,797 |
| CalquenceAcalabrutinib Maleate | 13 | $191,293 |
| JakafiRuxolitinib Phosphate | 11 | $187,387 |
| NinlaroIxazomib Citrate | 13 | $166,822 |
| VenclextaVenetoclax | 16 | $141,760 |
| EliquisApixaban | 141 | $114,663 |
| VerzenioAbemaciclib | 13 | $97,888 |
| CreonLipase/Protease/Amylase | 11 | $60,083 |
| Fondaparinux Sodium | 13 | $16,427 |
| Anastrozole | 105 | $1,618 |
| Acyclovir | 60 | $916 |
| Hydroxyurea | 48 | $737 |
| Prochlorperazine Maleate | 48 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel | $15 | $243,09012 claims |
| Incyte CorporationJakafi | $25 | $187,38711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Albany
- Mihir RavalAlbany$767K
- Rahul RavillaAlbany$351K
- Ira ZackonAlbany$127K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.